Global prevalence, cascade of care, and prophylaxis coverage of hepatitis B in 2022: a modelling study

Result code in IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00023001%3A_____%2F23%3A00084679" target="_blank" >RIV/00023001:_____/23:00084679 - isvavai.cz</a>

Alternative codes found

RIV/00216224:14110/23:00131315 RIV/65269705:_____/23:00078262

Result on the web

<a href="https://www.sciencedirect.com/science/article/abs/pii/S2468125323001978?via%3Dihub" target="_blank" >https://www.sciencedirect.com/science/article/abs/pii/S2468125323001978?via%3Dihub</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1016/S2468-1253(23)00197-8" target="_blank" >10.1016/S2468-1253(23)00197-8</a>

Result language

angličtina

Original language name

Global prevalence, cascade of care, and prophylaxis coverage of hepatitis B in 2022: a modelling study

Original language description

Background The 2016 World Health Assembly endorsed the elimination of hepatitis B virus (HBV) infection as a public health threat by 2030; existing therapies and prophylaxis measures make such elimination feasible, even in the absence of a virological cure. We aimed to estimate the national, regional, and global prevalence of HBV in the general population and among children aged 5 years and younger, as well as the rates of diagnosis, treatment, prophylaxis, and the future burden globally. Methods In this modelling study, we used a Delphi process with data from literature reviews and interviews with country experts to quantify the prevalence, diagnosis, treatment, and prevention measures for HBV infection. The PRoGReSs Model, a dyn amic Markov model, was used to estimate the country, regional, and global prevalence of HBV infection in 2022, and the effects of treatment and prevention on disease burden. The future incidence of morbidity and mortality in the absence of additional interventions was also estimated at the global level. Findings We developed models for 170 countries which resulted in an estimated global prevalence of HBV infection in 2022 of 3.2% (95% uncertainty interval 2.7-4.0), corresponding to 257.5 million (216.6-316.4) individuals positive for HBsAg. Of these individuals, 36.0 million were diagnosed, and only 6.8 million of the estimated 83.3 million eligible for treatment were on treatment. The prevalence among children aged 5 years or younger was estimated to be 0.7% (0.6-1.0), corresponding to 5.6 million (4.5-7.8) children with HBV infection. Based on the most recent data, 85% of infants received three-dose HBV vaccination before 1 year of age, 46% had received a timely birth dose of vaccine, and 14% received hepatitis B immunoglobulin along with the full vaccination regimen. 3% of mothers with a high HBV viral load received antiviral treatment to reduce mother-to-child transmission. Interpretation As 2030 approaches, the elimination targets remain out of reach for many countries under the current frameworks. Although prevention measures have had the most success, there is a need to increase these efforts and to increase diagnosis and treatment to work towards the elimination goals.

Czech name

—

Czech description

—

Type

J_imp - Article in a specialist periodical, which is included in the Web of Science database

CEP classification

—

OECD FORD branch

30219 - Gastroenterology and hepatology

Project

—

Continuities

N - Vyzkumna aktivita podporovana z neverejnych zdroju

Publication year

2023

Confidentiality

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Name of the periodical

Lancet gastroenterology and hepatology [online]

ISSN

2468-1253

e-ISSN

2468-1253

Volume of the periodical

8

Issue of the periodical within the volume

10

Country of publishing house

US - UNITED STATES

Number of pages

29

Pages from-to

879-907

UT code for WoS article

001158110000001

EID of the result in the Scopus database

2-s2.0-85169786860